Finally, rhoifolin administration inhibited nuclear translocation of NF-κB via downregulation of phospho-IκBα and phospho-p65, and it also up-regulated IκBα, suggesting that it could be a promising adjunct for cisplatin in tumor treatment (Song et al., 2020[167]). This evidence concerns the gene NFKBIA and neoplasm.